Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Payables (2016 - 2025)

Purple Biotech has reported Payables over the past 7 years, most recently at $2.1 million for Q4 2022.

  • Quarterly Payables rose 44.74% to $2.1 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2022, up 44.74% year-over-year, with the annual reading at $2.1 million for FY2022, 44.74% up from the prior year.
  • Payables was $2.1 million for Q4 2022 at Purple Biotech, down from $2.8 million in the prior quarter.
  • Over five years, Payables peaked at $3.0 million in Q2 2020 and troughed at $705000.0 in Q4 2018.
  • The 5-year median for Payables is $1.4 million (2021), against an average of $1.6 million.
  • Year-over-year, Payables surged 244.37% in 2020 and then crashed 40.75% in 2022.
  • A 5-year view of Payables shows it stood at $705000.0 in 2018, then soared by 76.6% to $1.2 million in 2019, then dropped by 3.78% to $1.2 million in 2020, then rose by 22.95% to $1.5 million in 2021, then surged by 44.74% to $2.1 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Payables are $2.1 million (Q4 2022), $2.8 million (Q3 2022), and $1.2 million (Q2 2022).